March 9 (Reuters) - Eli Lilly said on Monday a small number of basic Medicare drug plans may not follow the $50 per month cap ...

By Dr. Liji Thomas, MD Stopping popular GLP-1 weight-loss drugs may reverse much of their benefit within a year, according to a large modeling analysis, raising questions about how long patients may ...

March 4, 2026 expert reaction to meta-analysis and modelling study on weight regain after stopping GLP-1 receptor agonists . A meta-analysis published in eClinicalMedicine looks a ...

A year after stopping taking weight-loss drugs such as Ozempic and Wegovy, people regain—on average—60% of their lost weight. But beyond this, their regained weight plateaus, with individuals managing ...

Dr. Bill Sun’s rethink is desperately needed as obesity escalates into a worldwide public health crisis. So far, no ...

“The GLP-1 landscape is expected to broaden significantly,” said Dr. Christopher McGowan, a gastroenterologist who runs a weight loss clinic in Cary, North Carolina. “For the first time, medical ...

Changes are coming in 2026 for GLP-1 drugs. Long defined by high prices, shortages and weekly injections, drugs including Wegovy and Zepbound are expected to be easier to access and afford. And new ...

Obesity and type 2 diabetes are deeply interconnected. Yet, many diabetes prevention programs fail to adequately treat ...

A new voluntary Medicare model starts in July, and it could save you $11,000 per year. But there are steps you need to take right now.